Treatment Of Acute Deep Vein Thrombosis Of The Lower Ext

下肢急性深静脉血栓的治疗

• 批准号: 6674032
• 负责人: Richard T Chang
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6674032
• 关键词: cardiovascular disorder chemotherapy; clinical trials; dosage; drug adverse effect; drug screening /evaluation; embolism; human subject; human therapy evaluation; limbs; lung imaging /visualization /scanning; patient oriented research; plasminogen activator; protein structure function; recombinant proteins; venous thrombosis

The objective of the study is to evaluate thrombolytic therapy using recombinant tissue plasminogen activator (rtPA) for treatment of acute deep vein thrombosis of the lower extremity. While the conventional therapy, anticoagulation alone, is highly effective in prevention of life threatening pulmonary embolism, it does not preserve venous function in the affected leg, often leading to postphlebitic syndromes in subsequent years. The study is designed to evaluate efficacy, safety, and cost of this form of treatment for restoration of venous function in the lower extremity. Since start of the study, 14 patients have been treated. All except one patient had significant improvement. Only two patients have had evidence of small pulmonary emboli during treatment, detected on ventilation perfusion lung scans that are obtained in all patients accepted into the protocol. None of these patients were clinically symptomatic. One patient developed a non-life-threatening biceps hematoma probably induced by automatic blood pressure monitoring during the rtPA treatment. No patients have required blood transfusions and no other complications have occurred.

本研究的目的是评价使用重组组织型纤溶酶原激活剂（rtPA）治疗急性下肢深静脉血栓形成的溶栓疗法。虽然传统的治疗，单独抗凝，是非常有效的预防危及生命的肺栓塞，它不保留静脉功能，在受影响的腿，往往导致静脉炎后综合征在随后的几年。该研究旨在评估这种治疗形式恢复下肢静脉功能的有效性、安全性和成本。自研究开始以来，已有14名患者接受了治疗。除一名患者外，其他所有患者均有明显改善。只有两名患者在治疗期间有小肺栓塞的证据，在方案接受的所有患者中获得的通气灌注肺扫描中检测到。这些患者均无临床症状。1例患者发生了非危及生命的二头肌血肿，可能是rtPA治疗期间自动血压监测引起的。没有患者需要输血，也没有发生其他并发症。